Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved

First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years COPENHAGEN, Denmark, March 14, 2023 /PRNewswire/ — Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation…